Clinical Overview
Droperidol is a butyrophenone antipsychotic indicated for the prevention and treatment of postoperative nausea and vomiting. Important Note: This medication carries a Boxed Warning for QT prolongation and potential cardiac arrhythmias, significantly limiting its clinical use and requiring careful patient selection and monitoring.
Primary Clinical Applications
Droperidol is indicated for prevention and treatment of postoperative nausea and vomiting when other antiemetics are ineffective or contraindicated. It was previously used for preoperative sedation and psychotic agitation but current use is limited due to cardiac safety concerns.
Mechanism and Safety Concerns
As a potent dopamine D2 receptor antagonist, droperidol provides effective antiemetic action but also blocks cardiac potassium channels, leading to QT prolongation. The FDA’s Boxed Warning has severely restricted its use to situations where benefits clearly outweigh risks.
Clinical Restrictions
Due to cardiac safety concerns, droperidol requires pre-treatment ECG screening, continuous cardiac monitoring during use, and careful patient selection. Many institutions have removed it from formularies or severely restricted its use in favor of safer alternatives.
Prescribing Information
Dosing & Administration
Postoperative Nausea/Vomiting:
- Prevention: 0.625-1.25 mg IV/IM
- Treatment: 0.625-1.25 mg IV/IM
- Maximum initial dose: 2.5 mg
- Additional doses: 1.25 mg if needed
Pre-treatment Requirements:
- 12-lead ECG to assess QT interval
- Serum electrolyte assessment
- Continuous cardiac monitoring during administration
Administration:
- Administer slowly IV over 2-5 minutes
- Monitor for 2-3 hours post-administration
Indications
- Prevention of postoperative nausea and vomiting
- Treatment of postoperative nausea and vomiting
- Use only when other antiemetics ineffective or contraindicated
Contraindications
- Known or suspected QT prolongation
- Congenital long QT syndrome
- History of arrhythmias
- Electrolyte abnormalities (hypokalemia, hypomagnesemia)
- Concurrent QT-prolonging medications
- Known hypersensitivity to droperidol
Warnings & Precautions
- Boxed Warning: QT prolongation and potential for torsades de pointes
- Cardiac monitoring: ECG required before and during use
- Electrolyte monitoring: Correct abnormalities before administration
- Risk factors: Age >65, alcohol abuse, bradycardia, cardiac disease
- Extrapyramidal symptoms: May occur with higher doses
Drug Interactions
- QT-prolonging drugs: Contraindicated (quinidine, procainamide, amiodarone)
- CNS depressants: Enhanced sedation
- Class IA and III antiarrhythmics: Increased arrhythmia risk
- Phenothiazines: Additive QT effects
Adverse Reactions
Common:
- Drowsiness, restlessness, anxiety, extrapyramidal symptoms
Serious:
- QT prolongation, torsades de pointes, cardiac arrest
Other:
- Hypotension, tachycardia, laryngospasm
Special Populations
- Elderly: Increased risk of QT prolongation and adverse effects
- Pregnancy: Category C – use only if benefits outweigh risks
- Hepatic impairment: Use with extreme caution
- Renal impairment: Monitor closely for adverse effects
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
